Schrodinger Inc Ordinary Shares SDGR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SDGR is a good fit for your portfolio.
News
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
-
Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
-
Schrödinger to Participate in Upcoming Investor Conferences
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28
Trading Information
- Previous Close Price
- $24.81
- Day Range
- $24.02–24.86
- 52-Week Range
- $20.76–59.24
- Bid/Ask
- $23.76 / $25.25
- Market Cap
- $1.74 Bil
- Volume/Avg
- 568,016 / 883,625
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.59
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
- Sector
- Healthcare
- Industry
- Health Information Services
- Stock Style Box
- Small Core
- Total Number of Employees
- 787
- Website
- https://www.schrodinger.com
Comparables
Valuation
|
Metric
|
SDGR
|
RXRX
|
ABCL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.26 | 4.01 | 1.01 |
Price/Sales | 8.59 | 37.61 | 30.49 |
Price/Cash Flow | — | — | — |
Price/Earnings
SDGR
RXRX
ABCL
Financial Strength
|
Metric
|
SDGR
|
RXRX
|
ABCL
|
|---|---|---|---|
Quick Ratio | 4.13 | 4.24 | 6.93 |
Current Ratio | 4.25 | 4.70 | 7.33 |
Interest Coverage | — | −3,620.07 | — |
Quick Ratio
SDGR
RXRX
ABCL
Profitability
|
Metric
|
SDGR
|
RXRX
|
ABCL
|
|---|---|---|---|
Return on Assets (Normalized) | −19.89% | −41.77% | −6.10% |
Return on Equity (Normalized) | −28.56% | −59.93% | −7.74% |
Return on Invested Capital (Normalized) | −23.39% | −57.52% | −10.03% |
Return on Assets
SDGR
RXRX
ABCL
Health Information Services Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
GEHC
| GE HealthCare Technologies Inc Common Stock | — | Bmfmrq | $39.4 Bil | |
VEEV
| Veeva Systems Inc Class A | Fkykbmnj | Tjs | $32.4 Bil | |
SOLV
| Solventum Corp | — | Qfpgt | $11.0 Bil | |
MTHRF
| M3 Inc | — | Vkmtmm | $8.3 Bil | |
MTHRY
| M3 Inc ADR | — | Pwykdds | $8.2 Bil | |
PMCUF
| Pro Medicus Ltd | — | Xwkvkz | $7.2 Bil | |
HQY
| HealthEquity Inc | — | Dzgxr | $6.8 Bil | |
RCM
| R1 RCM Inc | — | Lxws | $5.0 Bil | |
DOCS
| Doximity Inc Class A | — | Zmchch | $4.5 Bil | |
EVH
| Evolent Health Inc Class A | — | Qjhmm | $3.3 Bil |